Hainan Shuangcheng Pharmaceuticals Co., Ltd.

Symbol: 002693.SZ

SHZ

5.16

CNY

Market price today

  • 2237.9007

    P/E Ratio

  • -128.6793

    PEG Ratio

  • 2.14B

    MRK Cap

  • 0.00%

    DIV Yield

Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693-SZ) Financial Statements

On the chart you can see the default numbers in dynamics for Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ). Companys revenue shows the average of 210.449 M which is 0.099 % gowth. The average gross profit for the whole period is 142.867 M which is 0.105 %. The average gross profit ratio is 0.675 %. The net income growth for the company last year performance is -0.792 % which equals -2.063 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Hainan Shuangcheng Pharmaceuticals Co., Ltd., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 0.066. In the realm of current assets, 002693.SZ clocks in at 252.394 in the reporting currency. A significant portion of these assets, precisely 146.01, is held in cash and short-term investments. This segment shows a change of 0.896% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 8.794, if any, in the reporting currency. This indicates a difference of -49.165% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 0 in the reporting currency. This figure signifies a year_over_year change of 0.228%. Shareholder value, as depicted by the total shareholder equity, is valued at 513.548 in the reporting currency. The year over year change in this aspect is 0.066%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 40.967, with an inventory valuation of 65.41, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 164.91. Account payables and short-term debt are 15.5 and 205.3, respectively. The total debt is 205.3, with a net debt of 193.11. Other current liabilities amount to 73.61, adding to the total liabilities of 330.08. Lastly, the referred stock is valued at 0, if it exists.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009

balance-sheet.row.cash-and-short-term-investments

512.2114677100
95.5
68.1
31.7
25
246.2
85.4
346.8
446.8
33.6
149.8
9.9

balance-sheet.row.short-term-investments

447.02133.855.494.3
52.8
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

144.814133.144.6
82.2
69.2
244.7
84.2
201.1
102.7
65.8
36.1
50.4
23.9
16.4

balance-sheet.row.inventory

291.7565.455.252.8
47.6
86.3
119.9
34.2
28.3
53.1
30.6
23.5
12.2
10.4
9.8

balance-sheet.row.other-current-assets

0.0500.10
0
148.6
161.7
8
3.4
380
220
161
-0.8
-2.5
-4.3

balance-sheet.row.total-current-assets

948.81252.4165.4197.5
225.4
372.1
557.9
151.4
479
621.2
663.2
667.4
95.5
181.6
31.8

balance-sheet.row.property-plant-equipment-net

1849.45471.8504.7541
601.1
637.8
679.5
658.9
443.2
264.1
213.3
182.1
133.8
54.2
53.4

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

668.54164.9156.9134.4
115.2
96.5
101.2
105.9
134.2
48.2
33.5
33.3
18.2
16.4
12.1

balance-sheet.row.goodwill-and-intangible-assets

668.54164.9156.9134.4
115.2
96.5
101.2
105.9
134.2
48.2
33.5
33.3
18.2
16.4
12.1

balance-sheet.row.long-term-investments

42.288.817.325.9
3.1
3.3
3.7
215.1
412.9
0
0
0
0
0
0

balance-sheet.row.tax-assets

3.67110.7
0.7
1.5
1.2
3
5.9
4
2.6
2.4
0.3
0.2
0.2

balance-sheet.row.other-non-current-assets

53.6612.29.18.3
5.4
9
37.3
246.4
487.9
6
4.4
1.5
0.2
0.2
0.3

balance-sheet.row.total-non-current-assets

2617.6658.6689.1710.2
725.6
748.1
819.2
1014.1
1071.1
322.3
253.9
219.3
152.6
71.1
66

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

3566.42911854.6907.7
951
1120.2
1377.1
1165.5
1550.2
943.5
917
886.7
248.1
252.7
97.9

balance-sheet.row.account-payables

59.5515.517.215.4
9.9
11.8
80.5
28.5
13.2
8.9
10.7
10.7
7.1
3.9
7.5

balance-sheet.row.short-term-debt

774.46205.30.355.7
0.3
0
0
190
345
0
0
0
0
0
0

balance-sheet.row.tax-payables

23.8512.87.26.3
10.1
5.3
8.8
4.5
11.9
7.2
8.3
6.7
4
4.5
4.5

balance-sheet.row.long-term-debt-total

00167167
167
306
367
297
145
0
0
0
0
0
0

Deferred Revenue Non Current

30.417.68.910.3
10.5
31.1
32.8
33.8
32
26.6
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

12.16---
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

144.4773.61.81.5
13.3
95
120.1
36.6
86.5
13.8
18.3
14.3
10.7
89.3
10.6

balance-sheet.row.total-non-current-liabilities

42.5610.7179.4180
179.1
343.7
414.8
357.3
177.9
27.3
17.4
15.9
2.1
1.8
1.8

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

0000
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

1235.79330.1287.8309.4
272.7
450.6
615.4
612.4
622.6
50
46.4
40.8
19.8
94.9
19.9

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

1662.29414.7412405
405
405
405
405
419.2
270
180
120
90
90
5

balance-sheet.row.retained-earnings

-1173.2-296.2-305.2-284.6
-231.3
-256
-186.5
-192.8
195.6
174.1
157.1
138.9
77.7
14.3
65.8

balance-sheet.row.accumulated-other-comprehensive-income-loss

1000.9287.282.286
86
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

600.88307.9292.9286.5
286.5
373
372.9
340.9
312.8
449.4
533.6
586.9
60.5
53.5
7.2

balance-sheet.row.total-stockholders-equity

2090.9513.5481.8492.9
546.3
522.1
591.4
553.1
927.6
893.6
870.6
845.8
228.2
157.8
77.9

balance-sheet.row.total-liabilities-and-stockholders-equity

3566.42911854.6907.7
951
1120.2
1377.1
1165.5
1550.2
943.5
917
886.7
248.1
252.7
97.9

balance-sheet.row.minority-interest

239.7467.484.9105.4
132
147.6
170.3
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

2330.63580.9566.8598.3
678.3
669.7
761.7
553.1
927.6
893.6
870.6
845.8
228.2
157.8
77.9

balance-sheet.row.total-liabilities-and-total-equity

3566.42---
-
-
-
-
-
-
-
-
-
-
-

Total Investments

447.02133.855.494.3
52.8
3.3
0
207
477.3
0
0
0
0
0
0

balance-sheet.row.total-debt

774.46205.3167.3222.7
167.3
306
367
487
490
0
0
0
0
0
0

balance-sheet.row.net-debt

709.27193.1145.6216.9
124.6
237.9
335.3
462
243.8
-85.4
-346.8
-446.8
-33.6
-149.8
-9.9

Cash Flow Statement

The financial landscape of Hainan Shuangcheng Pharmaceuticals Co., Ltd. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 0.040. The company recently extended its share capital by issuing 0, marking a difference of 0.664 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 19.57 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to -85071692.340 in the reporting currency. This is a shift of -3.578 from the previous year. In the same period, the company recorded 57.54, 0, and -12, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated -11.13 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 68.07, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009

cash-flows.row.net-income

0.93-8.5-40.8-79.9
9
-92.1
1.3
-388.4
52.7
58.9
66.8
68
70.4
64.2
32.1

cash-flows.row.depreciation-and-amortization

16.0657.554.357.1
59
56.1
43.5
29.2
20.7
17.4
12.6
7.6
5.7
5
3.7

cash-flows.row.deferred-income-tax

5.29-0.40.41.2
1.5
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

8.36.97.2-1.2
-1.5
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

-23.72-4.514.9-12.2
26.1
60.4
-37.2
112
-29.2
-12.3
-10.9
5.7
-10.3
-12.1
5

cash-flows.row.account-receivables

-13.83-13.85.439.8
8.2
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

-9.89-9.9-4.8-4.3
39.6
31.3
-89.6
-6.2
14.2
-22.4
-7.2
-11.3
-1.8
-0.6
-2.4

cash-flows.row.account-payables

019.613.8-48.9
-23.2
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

0-0.40.41.2
1.5
29.1
52.3
118.2
-43.4
10.2
-3.7
16.9
-8.5
-11.5
7.4

cash-flows.row.other-non-cash-items

-5.52-25.8-12.524.5
-27.6
22.5
-30.1
285.8
2.1
-13
-12
-1.1
0.3
-1.8
3.5

cash-flows.row.net-cash-provided-by-operating-activities

-0.08000
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-39.11-33-31.6-51.6
-51.5
-22.4
-70.2
-183
-289.7
-115.9
-65.1
-57.9
-107.1
-9.5
-23.3

cash-flows.row.acquisitions-net

30.812721.753.6
74
0
0.7
2
0.1
0
65.1
57.9
0
-1
0

cash-flows.row.purchases-of-investments

-418.83-471-256.2-637.2
-507.6
-775.3
-315.3
-8
-835.3
-1850
-2070.6
-441
0
-160
0

cash-flows.row.sales-maturities-of-investments

456.59391.9299.2615.3
599.4
915.9
302
6.4
729
1704
2024
280.9
0
161.4
0

cash-flows.row.other-investing-activites

000-51.6
-51.5
7.6
12.7
2.2
-0.7
-15.1
-65.1
-57.9
0
0
0.1

cash-flows.row.net-cash-used-for-investing-activites

29.47-85.133-71.5
62.8
125.9
-69.9
-180.4
-396.5
-277.1
-111.7
-218
-107.1
-9.2
-23.2

cash-flows.row.debt-repayment

-60.74-12-55.3-1.8
-139
-106
-475
-196.4
-70
0
0
0
0
0
-16

cash-flows.row.common-stock-issued

0000
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

-8.7-11.1-9.1-9.8
-10.1
-16.7
-7.5
-25.2
-43
-36
-44
0
-75.1
0
-16.3

cash-flows.row.other-financing-activites

38.3468.123.857
-5.3
-11.4
586.6
209.8
553.9
0
0
550
0
93.7
16

cash-flows.row.net-cash-used-provided-by-financing-activities

-31.144.9-40.645.4
-154.3
-134
104.1
-11.7
440.9
-36
-44
550
-75.1
93.7
-16.3

cash-flows.row.effect-of-forex-changes-on-cash

-0.020.1-0.1-0.3
0
-2.7
-3.4
1.1
0.7
-0.3
0
0.1
-0.1
0
0

cash-flows.row.net-change-in-cash

1.46-14.815.8-36.9
-24.9
36
8.2
-152.4
91.4
-262.4
-99.2
412.4
-116.2
139.9
4.8

cash-flows.row.cash-at-end-of-period

59.796.821.65.8
42.7
67.6
31.6
23.4
175.8
84.4
346.8
446
33.6
149.8
9.9

cash-flows.row.cash-at-beginning-of-period

58.3321.65.842.7
67.6
31.6
23.4
175.8
84.4
346.8
446
33.6
149.8
9.9
5.2

cash-flows.row.operating-cash-flow

-0.0825.223.6-10.5
66.6
46.8
-22.5
38.6
46.2
51
56.4
80.2
66.1
55.3
44.3

cash-flows.row.capital-expenditure

-39.11-33-31.6-51.6
-51.5
-22.4
-70.2
-183
-289.7
-115.9
-65.1
-57.9
-107.1
-9.5
-23.3

cash-flows.row.free-cash-flow

-39.19-7.8-8.1-62.1
15.1
24.5
-92.7
-144.3
-243.4
-64.9
-8.6
22.3
-41.1
45.8
20.9

Income Statement Row

Hainan Shuangcheng Pharmaceuticals Co., Ltd.'s revenue saw a change of -0.142% compared with the previous period. The gross profit of 002693.SZ is reported to be 186.47. The company's operating expenses are 215.79, showing a change of -23.662% from the last year. The expenses for depreciation and amortization are 57.54, which is a 0.059% change from the last accounting period. Operating expenses are reported to be 215.79, which shows a -23.662% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 0.422% year-over-year growth. The operating income is -24.48, which shows a -0.422% change when compared to the previous year. The change in the net income is -0.792%. The net income for the last year was -8.5.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009

income-statement-row.row.total-revenue

259.14274.8320.3269.4
346.6
337.2
246.8
145.1
231
161.2
149.6
129.7
133.5
112.9
88.2

income-statement-row.row.cost-of-revenue

77.4388.381.460.2
95.1
120.9
91.5
69.9
102.1
55.9
52.8
37.1
33.7
28.4
28.9

income-statement-row.row.gross-profit

181.71186.5238.9209.3
251.5
216.4
155.3
75.2
128.8
105.3
96.8
92.5
99.8
84.5
59.2

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

14.15---
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

14.02---
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

115.8---
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

71.7763.26969.7
41.5
-3.1
2.2
4.2
5.1
-0.4
3.5
6.6
2.5
0.6
0.9

income-statement-row.row.operating-expenses

210.16215.8282.7264.6
272.7
283.8
182.9
179.3
73.4
54.2
42
26.5
23.6
15.1
20.8

income-statement-row.row.cost-and-expenses

287.59304.1364.1324.8
367.8
404.7
274.4
249.2
175.5
110.1
94.7
63.7
57.3
43.4
49.7

income-statement-row.row.interest-income

0.10.10.10.1
0.6
0.3
0.3
0.2
0.9
5
7.9
6.2
1.6
0.3
0

income-statement-row.row.interest-expense

10.1511.2910
9.8
17.5
16.6
15.3
16.1
4.6
0
0
0
0
0.3

income-statement-row.row.selling-and-marketing-expenses

115.8---
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-0.0515.62-25.6
24.3
-25.9
30.7
-281
6.8
18
23.8
13.9
3.8
2.7
-2.6

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

71.7763.26969.7
41.5
-3.1
2.2
4.2
5.1
-0.4
3.5
6.6
2.5
0.6
0.9

income-statement-row.row.total-operating-expenses

-0.0515.62-25.6
24.3
-25.9
30.7
-281
6.8
18
23.8
13.9
3.8
2.7
-2.6

income-statement-row.row.interest-expense

10.1511.2910
9.8
17.5
16.6
15.3
16.1
4.6
0
0
0
0
0.3

income-statement-row.row.depreciation-and-amortization

-9.9257.554.357.1
59
56.1
43.5
29.2
20.7
17.4
12.6
7.6
5.7
5
3.7

income-statement-row.row.ebitda-caps

-22.8---
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-12.88-24.5-42.3-53.2
-13.7
-90.2
0.9
-389.1
57.4
69.7
75.2
73.3
77.9
71.5
38.7

income-statement-row.row.income-before-tax

-12.93-8.9-40.4-78.8
10.5
-93.4
3.1
-385.1
62.3
69.1
78.6
80
80
72.2
35.9

income-statement-row.row.income-tax-expense

-8.64-0.40.41.2
1.5
-1.2
1.8
3.3
9.6
10.2
11.9
12
9.6
7.9
3.8

income-statement-row.row.net-income

0.93-8.5-40.8-79.9
9
-69.5
6.3
-388.4
52.7
58.9
66.8
68
70.4
64.2
32.1

Frequently Asked Question

What is Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) total assets?

Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) total assets is 911018789.000.

What is enterprise annual revenue?

The annual revenue is 100763670.000.

What is firm profit margin?

Firm profit margin is 0.701.

What is company free cash flow?

The free cash flow is -0.095.

What is enterprise net profit margin?

The net profit margin is 0.004.

What is firm total revenue?

The total revenue is -0.050.

What is Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) net profit (net income)?

The net profit (net income) is -8496001.960.

What is firm total debt?

The total debt is 205303152.000.

What is operating expences number?

The operating expences are 215787255.000.

What is company cash figure?

Enretprise cash is 3712099.000.